Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinical Trials Transparency: EMA Delay Gives Industry Initiative More Time To Take Root

This article was originally published in The Pink Sheet Daily

Executive Summary

EMA’s plans for access to clinical trials data not set to be ready until well into 2014.

You may also be interested in...



EMA's Walks Fine Line On How It Will Publish Clinical Study Reports

In finalizing its policy on publishing clinical study reports, EMA stresses redactions of commercially confidential information will be rare, but critics still say it is favoring the pharma industry.

Clinical Data Transparency Would Counter-Balance Off-Label Promotion – NEJM

Giving independent researchers access to patient-level data and requiring public release of clinical study reports would help to offset the weakening of FDA’s oversight caused by industry’s First Amendment victories, a Boston University professor says.

Confidentiality Definition Comes Closer After AbbVie Drops EMA Cases

AbbVie’s decision to drop two cases against the EMA is likely to boost clinical trial transparency as well as bring drug regulators and the industry closer to a joint definition of commercial confidentiality.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075171

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel